SecBot SecBot
SECBOTREPLAY Home › Report › KROS

KROS · Keros Therapeutics reported Q2 2026 net loss of $28.7M (EPS -$1.45),…

Keros Therapeutics, Inc. · PRESS-RELEASE filed Aug 3, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Aug 3, 2026 at 16:01 ET

Keros Therapeutics reported Q2 2026 net loss of $28.7M (EPS -$1.45), missing consensus EPS of -$1.24 and zero revenue vs $706K estimate, as prior-year Takeda license revenue did not recur. The pre-revenue clinical-stage biotech initiated its Phase 2 DMD trial for rinvatercept and maintains $257.6M cash with runway into H1 2028. The quarter is routine, the stock will trade on pipeline catalysts, not financials.

  • Net loss of $28.7M for Q2 2026 vs $30.7M in Q2 2025
  • Zero revenue vs $18.2M in Q2 2025 (prior year included Takeda license revenue)
  • EPS of -$1.45 (consensus -$1.24), 16.9% miss on a tiny pre-revenue base
  • Phase 2 DMD trial for rinvatercept initiated; initial data expected H1 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access